17:19 , Dec 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Dermatophagoides pteronyssinus peptidase 1 (DERP1)

Inflammation INDICATION: Allergy; asthmaIn vitro and rat studies suggest inhibiting the enzymatic activity of house dust mite (HDM) allergens could help treat allergic asthma. Structural modeling and chemical synthesis identified a series of pyruvamide analogs...
08:00 , Jan 27, 2003 |  BC Week In Review  |  Clinical News

Immunodrug Qa-Derp1: Phase I

Updated interim results from an open-label, Swiss Phase I study showed that 12 volunteers receiving a 50 ?g subcutaneous or intramuscular Qa-Derp1 injection had antibody responses with ELISA titers between 1/3,000 and 1/40,000 4 weeks...
08:00 , Dec 9, 2002 |  BC Week In Review  |  Clinical News

Qa-Derp1 Immunodrug: Phase I

Interim results from an open-label, Swiss Phase I study in 24 volunteers showed Qa-Derp1 was well tolerated on initial immunization. Three subjects reported a mild local irritation and no systemic effects were reported. Subcutaneous and...